2023 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial | Rha, Sun Young; Oh, Do-Youn; Yañez, Patricio; Bai, Yuxian; Ryu, Min-Hee; Lee, Jeeyun; Rivera, Fernando; Alves, Gustavo Vasconcelos; Garrido, Marcelo; Shiu, Kai-Keen; Fernández, Manuel González; Li, Jin; Lowery, Maeve A; Çil, Timuçin; Cruz, Felipe Melo; Qin, Shukui; Luo, Suxia; Pan, Hongming; Wainberg, Zev A; Yin, Lina; Bordia, Sonal; Bhagia, Pooja; Wyrwicz, Lucjan S; KUN-HUEI YEH | The Lancet. Oncology | 21 | | |